These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. The mechanism of naked DNA uptake and expression. Wolff JA; Budker V Adv Genet; 2005; 54():3-20. PubMed ID: 16096005 [TBL] [Abstract][Full Text] [Related]
63. Scaleable processes for the manufacture of therapeutic quantities of plasmid DNA. Shamlou PA Biotechnol Appl Biochem; 2003 Jun; 37(Pt 3):207-18. PubMed ID: 12683955 [TBL] [Abstract][Full Text] [Related]
64. Human clinical trials of plasmid DNA vaccines. Liu MA; Ulmer JB Adv Genet; 2005; 55():25-40. PubMed ID: 16291211 [TBL] [Abstract][Full Text] [Related]
66. Upstream processing of plasmid DNA for vaccine and gene therapy applications. Tejeda-Mansir A; Montesinos RM Recent Pat Biotechnol; 2008; 2(3):156-72. PubMed ID: 19075863 [TBL] [Abstract][Full Text] [Related]
67. From plasmids to protection: a review of DNA vaccines against infectious diseases. Laddy DJ; Weiner DB Int Rev Immunol; 2006; 25(3-4):99-123. PubMed ID: 16818367 [TBL] [Abstract][Full Text] [Related]
68. Affinity chromatography approaches to overcome the challenges of purifying plasmid DNA. Sousa F; Prazeres DM; Queiroz JA Trends Biotechnol; 2008 Sep; 26(9):518-25. PubMed ID: 18675479 [TBL] [Abstract][Full Text] [Related]
69. Processing of plasmid DNA with ColE1-like replication origin. Wang Z; Yuan Z; Hengge UR Plasmid; 2004 May; 51(3):149-61. PubMed ID: 15109822 [TBL] [Abstract][Full Text] [Related]
70. DNA vaccination for cancer treatment. Spooner RA; Deonarain MP; Epenetos AA Gene Ther; 1995 May; 2(3):173-80. PubMed ID: 7614247 [TBL] [Abstract][Full Text] [Related]
71. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Sullivan SM; Doukas J; Hartikka J; Smith L; Rolland A Expert Opin Drug Deliv; 2010 Dec; 7(12):1433-46. PubMed ID: 21118032 [TBL] [Abstract][Full Text] [Related]
72. Production of plasmid DNA for pharmaceutical use. Voss C Biotechnol Annu Rev; 2007; 13():201-22. PubMed ID: 17875478 [TBL] [Abstract][Full Text] [Related]
73. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells. Honma M Environ Mol Mutagen; 2005; 45(2-3):162-76. PubMed ID: 15688360 [TBL] [Abstract][Full Text] [Related]
74. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Li J; Makrigiorgos GM Biochem Soc Trans; 2009 Apr; 37(Pt 2):427-32. PubMed ID: 19290875 [TBL] [Abstract][Full Text] [Related]
76. Structural instability of plasmid biopharmaceuticals: challenges and implications. Oliveira PH; Prather KJ; Prazeres DM; Monteiro GA Trends Biotechnol; 2009 Sep; 27(9):503-11. PubMed ID: 19656584 [TBL] [Abstract][Full Text] [Related]
77. Engineering of bacterial strains and vectors for the production of plasmid DNA. Bower DM; Prather KL Appl Microbiol Biotechnol; 2009 Apr; 82(5):805-13. PubMed ID: 19205691 [TBL] [Abstract][Full Text] [Related]
78. Biomedical application of plasmid DNA in gene therapy: a new challenge for chromatography. Sousa F; Passarinha L; Queiroz JA Biotechnol Genet Eng Rev; 2010; 26():83-116. PubMed ID: 21415877 [TBL] [Abstract][Full Text] [Related] [Previous] [New Search]